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Background: Active surveillance (AS) for low-risk prostate cancer (PCa) appears to provide excellent long-
term PCa-specific and overall survival. The choice for AS as initial treatment is mainly based on avoiding 
side effects from invasive treatment; but AS entails regular check-ups and the possibility of still having to 
switch or deciding to switch to invasive treatment. Here, we assessed the long-term follow-up data from AS 
in real life clinical practices.
Methods: Data from the first 500 men, enrolled in PRIAS before July 2008 by 30 centers across 8 
countries, were analyzed to provide long-term follow-up results. Men were advised to be regularly examined 
with prostate-specific antigen (PSA) tests, digital rectal examinations, and prostate biopsies. Men were 
advised to switch to invasive treatment if they had disease reclassification [Gleason score (GS) ≥3+4 on 
biopsy, more than two positive biopsy cores, a stage higher than cT2] or a PSA-doubling time of 0–3 years. 
We assessed time on AS, outcomes and reasons for discontinuing AS, and rates of potential unnecessary 
biopsies and treatments. 
Results: The median follow-up time was 6.5 years. During this period, 325 (65%) men discontinued after a 
median of 2.3 years and 121 (24%) men had no recent (>1 year) data-update after a median of 7.3 years. The 
remaining 54 (11%) men were confirmed to be still on AS. Most men discontinued based on protocol advice; 
38% had other reasons. During follow-up, 838 biopsy sessions were performed of which 79% to 90% did not 
lead to reclassification, depending on the criteria. Of the 325 discontinued men, 112 subsequently underwent 
radical prostatectomy (RP), 126 underwent radiotherapy, 57 switched to watchful waiting (WW) or died, 
and 30 had another or unknown treatment. RP results were available of 99 men: 34% to 68%, depending on 
definition, had favorable outcomes; 50% of unfavorable the outcomes occurred in the first 2 years. Of the 30 
(6%) men who died, 1 man died due to PCa.
Conclusions: These data, reflecting real life clinical practice, show that more than half of men switched 
to invasive treatment within 2.3 years, indicating limitations to the extent in which AS is able to reduce the 
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Introduction
Since the use of prostate specific antigen (PSA) testing, 
the majority of newly diagnosed prostate cancer (PCa) 
patients are considered to have low risk of progression (1). 
Although PSA screening leads to a PCa mortality reduction, 
overdiagnosis and overtreatment of these low-risk PCa 
patients are still a substantial concern (1-4). To prevent 
overtreatment, active surveillance (AS) is increasingly 
recognized as a favorable alternative to direct radical 
therapy for men with low-risk PCa (5-8). Considering 
all relevant data, the US Preventive Services Task Force 
(USPSTF) has recently proposed to endorse physicians 
to counsel men on PSA screening (9). This change in the 
USPSTF recommendation is heavily based on a modeling 
study which suggests that greater use of AS for low-risk PCa 
may tilt the balance of benefits and harms in PSA screening 
in favor of screening (10). However, this study models a 
conservative management program without considering the 
harms of repeated biopsies nor considering the harms of 
unnecessary treatments which occur despite an AS strategy. 
Moreover, patients who initially start an AS strategy may 
switch to active treatment based on signs of progression or 
other reasons. Furthermore, there is no consensus around 
the appropriate conduct of AS and differences may exist 
between strictly controlled cohorts and real life clinical 
practice (11). In this study, we analyze long-term follow-
up data from the first 500 patients enrolled in the Prostate 
Cancer Research International Active Surveillance (PRIAS) 
study, representing real life clinical practice in both 
community and academic centers from around the world.
Methods
The PRIAS study is a prospective observational study, 
initiated in December 2006. It facilitates centers around 
the world in performing AS, by providing a web-based 
register (www.prias-project.org) with automatic evidence-
based and individualized strategy recommendations (12). 
Data entering is done by each participating physician and 
monitored by the coordinating study center (Erasmus MC, 
Rotterdam, The Netherlands). 
Study population 
We selected the first 500 PRIAS patients, all enrolled 
before July 2008, to analyze their long-term follow-up data. 
Patients who already were under surveillance before official 
initiation of PRIAS were only included if the PRIAS follow-
up protocol had been applied. These 500 patients have been 
part of previous reports (13-15).
PRIAS protocol
The recommended criteria for inclusion were Gleason 
score (GS) ≤3+3, stage ≤ cT2c, PSA ≤10 ng/mL, ≤2 cores 
positive for PCa, PSA-density ≤0.2 ng/mL/cm3, and fitness 
for curative treatment (13). The recommended follow-up 
strategy during the first 2 years after diagnosis was a PSA 
test every 3 months and a digital rectal examination (DRE) 
every 6 months. Thereafter, a PSA test every 6 months and 
a DRE once yearly was recommended. Standard repeat 
biopsies were scheduled 1, 4, 7, and 10 years after diagnosis 
and subsequently every 5 years. Yearly biopsies were 
only recommended if PSA-doubling time (PSA DT) was 
between 0 and 10 years. A bone scan was recommended if 
the PSA level was ≥20 ng/mL. The recommended criteria 
to switch to active treatment were GS >3+3 or more than 
two positive cores on biopsy, and stage higher than cT2. A 
PSA DT between 0 and 3 years was used to recommend a 
switch to active treatment until the end of 2014, but was 
dropped afterwards (13). Furthermore, the criteria for a 
switch to active treatment were adapted to incorporate 
magnetic resonance imaging (MRI) targeted biopsy findings 
in 2015, as described in a recent publication (13).
adverse effects of overdiagnosis. Therefore, despite guidelines stating that PCa diagnosis must be uncoupled 
from treatment, it remains important to avoid overdiagnosing PCa as much as possible. 
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Statistical analyses
We performed descriptive statistics to report baseline 
characteristics, biopsy outcomes, reasons for discontinuation, 
treatments after discontinuation, outcomes on radical 
prostatectomy (RP), and biochemical recurrence (BCR), 
metastases and death rates. Biopsy outcomes were divided 
in two categories: reclassification based on GS ≥3+4 only 
and reclassification based on GS ≥3+4 or ≥2 cores positive. 
RP outcomes were divided in 4 categories: low-risk PCa 
(GS 3+3, ≤cT2), intermediate-risk PCa Grade Group 2 (GS 
3+4, ≤cT2), intermediate-risk PCa Grade Group 3 (GS 4+3, 
≤cT2), and high-risk or locally advanced PCa (GS ≥4+4 or 
≥T3). BCR was defined as a PSA level ≥0.2 ng/mL after RP 
or a PSA level 2.0 ng/mL above the nadir after radiation 
therapy (RT).
Results
The first 500 patients included in PRIAS were followed 
prospectively by 30 centers across 8 countries (Table S2) 
until November 20, 2017. At diagnosis, the median age 
was 65.9 years, the median PSA was 5.3 ng/mL, and 
most patients had one positive biopsy core (69%) with 
GS 3+3 (100%) and a clinical stage T1c (80%) (Table 1). 
Fifteen patients (3%) did not comply to the recommended 
inclusion criteria and either had a PSA-density just above 
0.2 ng/mL/mL, a PSA just above 10 ng/mL or 3 cores 
positive for GS 3+3. 
During follow-up, a total of 838 biopsies sessions were 
performed in 427 patients, of which 48% underwent 2 or 
more surveillance biopsies (range 1–5). Of the remaining 
73 patients who did not have a surveillance biopsy, 50 
patients discontinued AS based on protocol advice (rising 
PSA, n=28), anxiety (n=15) or unknown reason (n=7); 
and 23 patients were lost to follow-up after a median of 
3.4 years. Based on the criteria GS ≥3+4 or >2 cores 
positive, 79% of the 838 biopsies did not lead to 
reclassification; based on the criterion GS ≥3+4, 90% of the 
biopsies would not have led to reclassification (Figure 1).
The median follow-up time, the time between first and 
last visit, was 6.5 years. After 5 and 10 years of follow-up, 
respectively, 224 (45%) and 68 (13.6%) patients were still 
on AS; 181 (36%) and 200 (40%) patients discontinued AS 
based on protocol advice; 39 (8%) and 48 (9.6%) patients 
discontinued due to anxiety, on own request or other 
reasons; 14 (3%) and 19 (3.8%) patients discontinued and 
were lost to follow-up; 20 (4%) and 55 (11%) patients were 
switched to watchful waiting (WW) or died; and 22 (4%) 
and 110 (22%) patients had no recent (>1 year) data-update 
(Figure 2).
Among the 500 patients, 325 (65%) discontinued AS after 
a median of 2.3 years. Subsequently, 112 patients underwent 
RP, 126 underwent radiotherapy, 57 switched to WW 
or died, and 30 had another or unknown treatment. RP 
results of 99 patients were available for analysis. Of the 99 
patients, 34% of patients had low-risk PCa (GS 3+3, ≤ cT2) 
and 33% of patients had intermediate-risk PCa Grade 
Group 2 (GS 3+4, ≤ cT2), 7% of patients had intermediate-
risk PCa Grade Group 3 (GS 4+3, ≤ cT2), and 25% of 
patients had high-risk or locally advanced PCa (GS ≥4+4 or 
≥ T3). Of the patients in the latter two groups, 62.5% had 
their active treatment within the first 2 years (Figure 3). 
Of the total 500 patients, 16 (3.2%) patients had BCR 
after a median of 2.8 years after RT (n=4) and RP (n=12). 
Four (0.8%) patients developed metastasis after a median of 
1.6 years after discontinuing AS (2 patients had switched to 
RP, 1 to RT, and 1 to WW). Of the 30 (6%) patients who 
Table 1 Patient characteristics at inclusion
Characteristics Results
Age, years 65.9 (60.0–70.9)
PSA, ng/mL 5.3 (3.8–6.7)
Prostate volume, cm3 42.5 (34.6–56.0)
PSA-density, ng/mL/cm3 0.12 (0.08–0.16)
No. of biopsy cores 8 [6–10]










Follow-up time, years 6.5 (3.1–8.4)
No. of follow-up visits 11 [5–18]
Data presented as median (IQR) or n (%). PSA, prostate specific 
antigen; IQR, interquartile range.
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died, after a median of 4.8 years after diagnosis, 1 patient 
died due to PCa. 
Discussion
AS is increasingly being used and is considered a solution 
to the widely recognized problem of overtreatment of 
screening detected low-risk PCa (8,9,16). The mortality 
outcomes of AS patients seem comparable to patients 
who choose direct radical treatment, but possibly with 
a higher risk of metastasis (17-19). Although evidence 
is not yet conclusive, these findings have led to several 
guidelines endorsing PSA screening and statements that 


































10% reclassification (GS ≥3+4)
90% no reclassification (GS ≤3+3)
21% reclassification (GS ≥3+3 or ≥2 cores positive)
79% no reclassification (GS ≤3+3 and <2 cores positive)
Biopsy reclassification based on gleason score and number of cores
Biopsy reclassification based on Gleason score only
150
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(Years)
Figure 1 Biopsy reclassification during follow-up.
Figure 2 Status during follow-up. AS, active surveillance.
Year 
0 1 2 3 4 5 6 7 8 9 10 11 12
 Still on AS 500 483 366 300 260 224 194 154 115 86 68 61 58
 Discontinued: watchfull waiting or died 0 1 6 13 16 20 26 42 49 54 55 55 56
 Discontinued: lost to follow-up 0 1 5 10 12 14 14 15 17 18 19 19 19
 Discontinued: anxiety, patient request, other 0 8 22 29 35 39 42 44 47 48 48 48 48
 Discontinued: based on protocol (GS ≥3+4, 
>2 cores positive, PSA-DT 0-3 yrs, >T2c)
0 7 101 145 163 181 189 192 196 199 200 200 201
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Time from diagnosis to radical prostectomy
Classification after radical prostatectomy
34.3% Low risk PCa (GS 3+3, ≤cT2)
33.3% Intermediate-risk PCa grade group 2 (GS 3+4, ≤cT2)
7.1% Intermediate-risk PCa grade group 3 (GS 4+3, ≤cT2)
25.3% High risk/locally advanced PCa (GS ≥4+4 or ≥cT3)
Figure 3 Radical prostatectomy results during follow-up. PCa, prostate cancer; GS, Gleason score.
when AS is used (9,20). 
In this study, we show that AS indeed seems a safe 
alternative to direct radical therapy, with only 3.2% of 
patients having BCR after a switch to radical treatment, 
0.8% of patients developing metastasis after discontinuing 
AS, and only one PCa death. However, there are some 
substantial drawbacks with AS which limit its capability to 
mitigate all harms associated with overdiagnosing low-risk 
PCa. In this current analysis, we found that at least 79% of 
surveillance biopsy sessions performed during follow-up 
can retrospectively be considered redundant, as they did not 
show reclassification. During this time period, the criteria 
for reclassification on biopsy were GS ≥3+4 or ≥2 cores 
positive. However, in 2016 the PRIAS study omitted the 
≥2 positive cores criteria for reclassification because it did 
not significantly predict unfavorable outcomes on RP (13). 
Therefore, retrospectively, the 90% of biopsy sessions 
without GS ≥3+4 can be considered redundant. Other AS 
cohorts show similar high rates of biopsy sessions which 
did not lead to reclassification based on the criteria of GS 
≥3+4 (21,22). Following a prostate biopsy, 0.5% to 6.9% 
of patients require hospital admission due to severe urinary 
tract infection or sepsis, and up to 25% experience other 
complaints (23), demonstrating that prostate biopsies should 
be avoided as much as possible. 
Furthermore, of the 99 patients who underwent RP, 
we found that at least one third of patients had favorable 
pathology (GS3+3, ≤ pT2) which even if left untreated, 
would not progress (24). Another third of patients appeared 
to have intermediate risk PCa Grade Group 2 (GS 3+4, 
≤ pT2), for at least some of whom it remains unclear 
whether they will have benefit from their switch to RP (25). 
The remaining one third of patients had unfavorable 
pathology (GS ≥4+3 or ≥ pT3), for whom a switch to active 
treatment was appropriate. However, as more than half of 
these patients had their RP within 2 years after diagnosis, 
we can assume that these patients were misclassified at 
diagnosis. As shown in previous analyses of PRIAS patients 
and other AS cohorts, risk stratification during AS lacks 
specificity to detect progression or misclassification within 
the window of curability, with under- and overtreatment as 
a result (13,26). 
Finally, after 5 and 10 years of follow-up, respectively, 
51% and 64% of the 500 patients had discontinued AS. 
Ten years after diagnosis, only 14% of the patients who 
originally started AS were confirmed to be still on AS. Of 
the remaining 22% of patients, no recent update (>1 year) 
was available, and these patients should be considered lost 
103Translational Andrology and Urology, Vol 7, No 1 February 2018
Transl Androl Urol 2018;7(1):98-105tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
to follow-up with the possibility of actually still being on 
AS or in the meantime having discontinued AS. In other 
AS cohorts, higher rates of patients still being on AS are 
reported, with 50% to 63.5% after 10 years (17,18,27), 
possibly explained by differences in inclusion and follow-
up criteria, and the less strictly controlled PRIAS protocol. 
Moreover, not all patients who switch to active treatment 
do so because of protocol based signs of progression. In this 
study, 48 (18%) of patients switched to active treatment 
because of anxiety or other reasons, comparable to the 23% 
of patients in the Johns Hopkins cohort (18).
This study has some limitations inherent to the initial 
facilitating setup of this observational study. Some men, for 
example, were lost to follow-up or did not have a recent 
data-update. As this is not a strictly controlled cohort, 
events might have occurred out of our scope. Furthermore, 
during the follow-up period of these patients, MRI was 
largely unavailable. Although MRI is more frequently used 
in contemporary AS strategies, including PRIAS, more data 
and longer follow-up are needed to evaluate the additional 
value of MRI in AS to detect misclassification and especially 
to detect progression (28-30). At least for now, MRI is not 
accurate enough to replace systematic re-biopsies (31). 
Future ways to improve the conduct of AS most likely 
involve incorporation of more sophisticated individualized 
risk stratification methods, based on MRI and other 
biomarkers (32,33).
Based on our findings here, however, AS seems not to 
solve the problem of overtreatment sufficiently. Therefore, 
improvement of the diagnostic pathway is an absolute must. 
With PSA-based screening, benefits (mortality reduction) 
and harms (unnecessary testing and overdiagnosis) go hand 
in hand (34). These harms could, however, be reduced 
by smarter screening using risk prediction tools to aid in 
the decision to have a PSA-test or to undergo a prostate 
biopsy (35). In addition, other biomarkers and MRI could 
be incorporated into the diagnostic pathway to secure the 
detection of potentially lethal PCa (36,37).
Conclusions
Although AS seems a favorable alternative to direct radical 
therapy for men with low-risk PCa, the ability of AS to 
prevent the harms associated with overdiagnosis has not yet 
been clearly defined in practice. During AS, despite its aim, 
many in retrospect-unnecessary biopsies are performed and 
risk stratification methods lack the specificity to prevent all 
of the overtreatment. Therefore, it remains important to 
avoid overdiagnosing PCa as much as possible.
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Admiraal de Ruyter Ziekenhuis te Goes/Vlissingen Netherlands Dr. J. Jaspars
Albert Schweitzer Ziekenhuis Netherlands Dr. R.M. Potjer
Albert Schweitzer Ziekenhuis Netherlands Dr. Rene Raaijmakers
Albert Schweitzer Ziekenhuis Netherlands Dr. W.M. Stomps
Albert Schweitzer Ziekenhuis Netherlands Dr. J.J. Vis
Albert Schweitzer Ziekenhuis Netherlands Dr. P.A. Wertheimer
Albert Schweitzer Ziekenhuis Netherlands Dr. A.G.M. Zeegers
Amphia Ziekenhuis Netherlands Dr. P.J. van den Broeke
Amphia Ziekenhuis Netherlands D. van der Schoot
Amphia Ziekenhuis Netherlands Drs. H. Jansen
Amphia Ziekenhuis Netherlands Ilze van Onna
Amphia Ziekenhuis Netherlands Dr. E.H.G.M. Oomens
Amphia Ziekenhuis Netherlands Dr. P.J. Posthumus
Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) Netherlands E. van Muilekom
Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) Netherlands Dr. H. van der Poel
BC Cancer Agency Canada Adam Kahnamelli
BC Cancer Agency Canada Alex Briede
BC Cancer Agency Canada Dana Matuszewski
BC Cancer Agency Canada Henry Lau
BC Cancer Agency Canada Devon Poznanski
Canisius-Wilhelmina Ziekenhuis Nijmegen Netherlands Dr. D.M. Somford
Canisius-Wilhelmina Ziekenhuis Nijmegen Netherlands Dr. H. Vergunst
Catharina Ziekenhuis Eindhoven Netherlands Dr. E.L. Koldewijn
Catharina Ziekenhuis Eindhoven Netherlands Dr. P.E.F. Stijns
Catharina Ziekenhuis Eindhoven Netherlands Dr. Wout Scheepens
Diakonessenhuis Utrecht Netherlands Dr. Karin van Dalen
Diakonessenhuis Utrecht Netherlands Roan Spermon
Emco Klinik, Salzburg Austria Dr. Andreas Jungwirth
Erasmus MC Netherlands Dr. W. Boellaard
Erasmus MC Netherlands Dr. J. Boormans
Erasmus MC Netherlands Dr. M.Busstra
Erasmus MC Netherlands Prof. Dr. F.H. Schröder
Erasmus MC Netherlands Dr. W. Kirkels
Erasmus MC Netherlands Dr. Meelan Bul
Erasmus MC Netherlands Dr. P. Verhagen
Erasmus MC Netherlands Dr. Marij Dinkelman-Smit
Erasmus MC Netherlands Wouter Roobol
Erasmus MC Netherlands L.D.F. Venderbos
Erasmus MC Netherlands A.R. Alberts
Erasmus MC Netherlands F-J. H. Drost
Hospital Virgen del Camino, Pamplona Spain Manuel Montesino
Kuopio University Hospital Finland Sirpa Aaltomaa
Krankenhaus der Barm. Brueder Germany Prof. Nikolaus Schmeller
Maasstad Hospital Rotterdam Netherlands Dr. D.C.D. De Lange
Maasstad Hospital Rotterdam Netherlands Dr. D. van den Ouden 
Medisch Spectrum Twente Netherlands Drs. Emile Alleman
Medisch Spectrum Twente Netherlands Drs. Boudewijn Santerse
Medisch Spectrum Twente Netherlands Dr. Henriette Leenknegt
Medisch Spectrum Twente Netherlands Dr. Maarten-Jan Pit
Medisch Spectrum Twente Netherlands Sing Khoe
Oulu University Hospital Finland Pekka Hellström
Reinier de Graaf Gasthuis Netherlands J. Hoeven
Rivas Care Group Netherlands Dr. R. Gilhuis
Rivas Care Group Netherlands Dr. H. Plancke
SIURO - Fondazione IRCCS Istituto Italy Tiziana Magnani
SIURO - Fondazione IRCCS Istituto Italy Maria Francesca Alvisi
SIURO - Fondazione IRCCS Istituto Italy Tiziana Rancati PhD
SIURO - Fondazione IRCCS Istituto Italy Silvia Catania
St. Franciscus Gasthuis Netherlands Dr. M. Asselman
St. Franciscus Gasthuis Netherlands Dr. Ilse van den Berg
St. Franciscus Gasthuis Netherlands Dr. J. Blom
St. Franciscus Gasthuis Netherlands Dr. E. Boevé
St. Franciscus Gasthuis Netherlands Dr. R. Nooter
St. Franciscus Gasthuis Netherlands Dr. J. Rietbergen
St. Franciscus Gasthuis Netherlands Dr. Stijn de Vries
University Hospital Muenster Germany Barbara Thielen
University Hospital Muenster Germany Dr. Sebastian Kemper
University Hospital Muenster Germany Klaus Kruse
University Hospital Muenster Germany Dr. A. Semjonow
University Hospital Muenster Germany Thomas Köpke
Universitair Ziekenhuis Gent Belgium Prof. W. Oosterlinck
Vlietland Ziekenhuis Netherlands Drs. Ilse van den Berg
Vlietland Ziekenhuis Netherlands Drs. Helene Wilkens
VU Medical Center Amsterdam Netherlands Dr. A.N. Vis
Westfries Gasthuis Netherlands Dr. Maicle Leter
Ziekenhuis Bernhoven Netherlands A.Q.H.J. Niemer
Ziekenhuisgroep Twente Netherlands Dr. E.B. Cornel
Ziekenhuisgroep Twente Netherlands Gerd-Jan Molijn
Table S2 Inclusions per center
Country Center Inclusions
The Netherlands Erasmus University Medical Center, Rotterdam 84
Netherlands Cancer Institute, Amsterdam 54
St. Franciscus Hospital, Rotterdam 48
Hospital group Twente, Enschede 30
Albert Schweitzer Hospital, Dordrecht 44
Admiraal de Ruyter Hospital, Goes 21
Reinier de Graaf Hospital, Delft 14
Medisch Spectrum Twente, Enschede 9
Amphia Hospital, Breda 7
Canisius-Wilhelmina Hospital, Nijmegen 7
Vlietland Hospital, Rotterdam 7
Hospital Bernhoven, Uden 5
Diakonessenhuis, Utrecht 4
VU University Medical Centre, Amsterdam 4
Ikazia Hospital, Rotterdam 2
Maasstad Hospital Rotterdam, Rotterdam 2
Rivas Care group, Gorinchem 2
Westfries Hospital, Hoorn 2
Catharina Hospital, Eindhoven 1
Ruwaard van Putten Hospital, Spijkenisse 1
Finland Helsinki University Central Hospital, Helsinki 66
Kuopio University Hospital, Kuopio 1
Oulu University Hospital, Päijät-Häme 1
Canada British Columbia Cancer Agency, Vancouver 38
Italy Fondazione IRCSS Istituto Nazionale dei Tumori, Milan 28
Germany University Hospital Muenster, Muenster 6
Krankenhaus der Barmherzige Brüder, Munich 2
Spain Hospital Virgen del Camino, Pamplona 5
Austria Emco Klinik, Salzburg 4
Belgium University Hospital Gent, Gent 1
